



**December 5, 2025**

## **Nevada Medicaid Web Announcement 3781**

### **Medicaid Services Manual Chapters Updated**

The following Medicaid Services Manual (MSM) chapters have been updated and posted on the Nevada Health Authority (NVHA) website:

- MSM Chapter 400 – Mental Health Services (effective October 1, 2025)

<https://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C400/Chapter400/>

Revisions to Medicaid Services Manual (MSM) Chapter 400 - Mental Health Services are being proposed to add Coordinated Specialty Care for beneficiaries experiencing their first episode of psychosis. Coordinated Specialty Care is the standard of care for treatment for individuals, typically in late adolescence to mid-20s experiencing their first episode of psychosis (FEP). It is an evidence-based, recovery-focused, team-based early intervention model that promotes access to care and shared decision-making among specialists, the person experiencing psychosis, and family member.

Proposed revisions to Medicaid Services Manual (MSM) Chapter 400 - Mental Health Services include the addition of Assertive Community Treatment (ACT) for individuals with serious and persistent mental illness. ACT is a team-based, community-focused treatment approach that provides comprehensive psychiatric treatment, rehabilitation, and support. Its goal is to improve functioning and help individuals remain in their communities, avoiding inpatient treatment.

- MSM Chapter 600 – Physician Services (effective January 1, 2026)

<https://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C600/Chapter600/>

Revisions to Medicaid Services Manual (MSM) Chapter 600 – Physician Services Section 603.4D are being proposed add coverage of cell-free fetal deoxyribonucleic acid (DNA) testing.

- MSM Chapter 1200 – Prescribed Drugs (effective October 6, 2025)

<https://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C1200/Chapter1200/>

Revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed Drugs are being proposed to update Appendix B Section 5.: (A) Abraxane® - Updated prior authorization (PA) Guidelines; Section (B). Anti-PD-1 Monoclonal Antibodies – (5.) Opdivo® – Updated Colorectal Cancer (CRC) and Hepatocellular Carcinoma (HCC); Section (D.) Bevacizumab – (1.)(f.) Updated CRC, (1.)(g.) Appendiceal Adenocarcinoma – Colon Cancer, (1.)(i.) HCC, (1.)(m.) Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer; (1.)(r.) updated Vaginal Cancer; and (2.) Updated Dosage Limits; Section (E.) Darzalex® – (1.)(c.) Updated Multiple Myeloma (MM), and (4.) Updated PA Guidelines; Section (F.) Darzalex Faspro® – (1.)(c.) Updated MM and (2.) Updated Dosage Limits for MM; Section (K.) Kadcyla® – Updated Universal Criteria, (1.)(d.) updated Central Nervous System (CNS) Cancer, (1.)(f.) updated Head and Neck Cancer, (2.)(a.) Removed Quantity Limit (max daily dose), (3.) Updated Renewal Criteria, (4.) Updated PA Guidelines; Section (M.) Long-Acting Granulocyte Colony Stimulating Factors – (1.) Updated Pegfilgrastim; Section (N.) Pemetrexed – (j.) Added Thyroid Carcinoma and (2.) Updated Dosage Limits; Section (O.) Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitors – (1.) Perjeta® – Update Breast Cancer, CNS Cancer, CRC, Appendiceal Adenocarcinoma – Colon Cancer, and Head and Neck Cancer, Dosage limits and Recertification Request; (2.) Trastuzumab – Updated Breast Cancer, Gastric, Esophageal and Esophagogastric Junction Cancers, CRC, Appendiceal Adenocarcinoma – Colon Cancer, Dosage Limits, and Recertification Request; Section (P.) CD20 Monoclonal Antibodies – (1.) Rituxan®, Truxima®, Ruxience™, Riabni™ – Updated Oncology Indications, Immunoglobulin G4-related disease (IgG4-RD), Dosing Limits and Recertification Request; Section (R.) Yervoy® – Updated Dosage Limits; Section (S.) Zynlonta® – Updated Dosage Limits and PA

Guidelines; Section (T.) Osteoporosis Agents – (b.) Prolia® and Jubbonti® – added Ospomyv®, Stoboclo®, Denosumab-dssb, and Conexence®/Denosumab-bnht; (c.) Xgeva® and Wyost® – Updated Dosing Limits. Appendix B was renamed from “Standard Therapeutic Drug Classes” to “Physician Administered Drugs” throughout the chapter.

- MSM Chapter 1700 – Therapy (effective January 1, 2026)

<https://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C1700/Chapter1700/>

Revisions to Medicaid Services Manual (MSM) Chapter 1700 – Therapy, Section 1703.1B are being proposed to remove prior authorization requirements for all Speech Language Pathology services provided to a recipient under the age of 26 for the treatment of a stutter (fluency disorder).

- MSM Chapter 4400 – Crisis Services (effective October 1, 2025)

[https://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C4400/Chapter\\_4400/](https://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C4400/Chapter_4400/)

Creation of Medicaid Services Manual (MSM) Chapter 4400 – Crisis Services is being proposed. The following crisis services are being removed from MSM Chapter 400 – Mental Health Services and being moved with revisions and updates to the new MSM Chapter 4400 - Crisis Intervention (CI), Designated Mobile Crisis Team (DMCT), and Crisis Stabilization Center (CSC). Additionally, MSM Chapter 4400 will include the following new community-based crisis services: Mobile Crisis Team (MCT) and Intensive Crisis Stabilization Service (ICSS) facility.